Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment also provides in vivo sampling services for the continuous monitoring of chemical changes in life; non-clinical and pathology services; analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees224
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable
Bioanalytical Systems (NASDAQ:BASI) Frequently Asked Questions
What is Bioanalytical Systems' stock symbol?
Bioanalytical Systems trades on the NASDAQ under the ticker symbol "BASI."
How were Bioanalytical Systems' earnings last quarter?
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced its quarterly earnings data on Monday, December, 23rd. The company reported $0.05 earnings per share for the quarter. The business earned $14.79 million during the quarter. View Bioanalytical Systems' Earnings History.
When is Bioanalytical Systems' next earnings date?
Has Bioanalytical Systems been receiving favorable news coverage?
News articles about BASI stock have trended somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bioanalytical Systems earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Bioanalytical Systems.
Are investors shorting Bioanalytical Systems?
Bioanalytical Systems saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 20,200 shares, a decrease of 51.3% from the January 15th total of 41,500 shares. Based on an average daily trading volume, of 66,600 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the shares of the company are short sold. View Bioanalytical Systems' Current Options Chain.
What other stocks do shareholders of Bioanalytical Systems own?
Who are Bioanalytical Systems' key executives?
Bioanalytical Systems' management team includes the folowing people:
- Mr. Philip A. Downing, Sr. VP of Preclinical Services (Age 49)
- Ms. Jill C. Blumhoff, CFO, VP of Fin. & Sec. (Age 43)
- Mr. Robert Leasure Jr., Pres, CEO & Director (Age 59)
- Dr. Peter T. Kissinger, Founder, Chairman Emeritus & Scientific Advisor (Age 74)
- Mr. D. Thomas Oakley, Chief Operating Officer
Who are Bioanalytical Systems' major shareholders?
Bioanalytical Systems' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.08%), Essex Investment Management Co. LLC (0.91%), Acadian Asset Management LLC (0.63%) and Magnus Financial Group LLC (0.21%). Company insiders that own Bioanalytical Systems stock include Daniel Thomas Oakley, Gregory Cole Davis, Jill Blumhoff, John E Sagartz, Peter Kissinger, Philip A Downing, R Matthew Neff, Robert Jr Leasure, Wendy Perrow and William D Pitchford. View Institutional Ownership Trends for Bioanalytical Systems.
Which institutional investors are selling Bioanalytical Systems stock?
Which institutional investors are buying Bioanalytical Systems stock?
BASI stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC and Essex Investment Management Co. LLC. Company insiders that have bought Bioanalytical Systems stock in the last two years include Daniel Thomas Oakley, Gregory Cole Davis, Jill Blumhoff, John E Sagartz, Peter Kissinger, Philip A Downing, R Matthew Neff, Robert Jr Leasure, Wendy Perrow and William D Pitchford. View Insider Buying and Selling for Bioanalytical Systems.
How do I buy shares of Bioanalytical Systems?
Shares of BASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Bioanalytical Systems' stock price today?
One share of BASI stock can currently be purchased for approximately $4.61.
MarketBeat Community Rating for Bioanalytical Systems (NASDAQ BASI)
MarketBeat's community ratings are surveys of what our community members think about Bioanalytical Systems and other stocks. Vote "Outperform" if you believe BASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
